Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy, M., Lecompte, T., Douxfils, J., Lessire, S., Dogné, J. M., Chatelain, B., Testa, S., Gouin-Thibault, I., Gruel, Y., Medcalf, R. L., ten Cate, H., Lippi, G., Mullier, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474970/
https://www.ncbi.nlm.nih.gov/pubmed/32922211
http://dx.doi.org/10.1186/s12959-020-00230-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474970/
https://www.ncbi.nlm.nih.gov/pubmed/32922211
http://dx.doi.org/10.1186/s12959-020-00230-1

Ejemplares similares